Bio-Techne 

$74
79
-$3.43-4.43% 今天

统计数据

当日最高
77.42
当日最低
73.89
52周最高
85.57
52周最低
51.79
成交量
1,106,183
平均成交量
895,704
市值
11.73B
市盈率
70.47
股息收益率
0.43%
股息
0.32

即将到来

股息

0.43%股息收益率
10年增长
0.24%
5年增长
N/A
3年增长
N/A
1年增长
N/A

收益

29Oct预期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一个
0.38
0.44
0.49
0.55
预期每股收益
0.383986
实际每股收益
N/A

人们还关注

此列表基于关注TECH的Stock Events用户的观察列表。这不是投资建议。

竞争者

这个列表是基于最近市场事件的分析。这不是投资建议。
Thermo Fisher Scientific
TMO
市值234.95B
Thermo Fisher Scientific提供了与Bio-Techne类似的广泛产品和服务,包括生命科学解决方案和分析仪器,使其成为直接竞争对手。
Danaher
DHR
市值194.5B
Danaher Corporation在生命科学和诊断等领域与Bio-Techne经营类似的业务,提供具有竞争力的产品和技术。
Illumina
ILMN
市值20.93B
Illumina, Inc.专注于基因组学和DNA测序技术,与Bio-Techne的基因组学和蛋白质组学产品竞争。
Agilent Technologies
A
市值41.06B
Agilent Technologies在生命科学、诊断和应用化学市场提供全面的解决方案,直接与Bio-Techne的分析和诊断产品竞争。
Waters
WAT
市值20.56B
Waters Corporation提供与Bio-Techne的色谱和质谱解决方案竞争的分析仪器、软件和服务。
Bio-Rad Laboratories
BIO
市值9.35B
Bio-Rad Laboratories, Inc.为生命科学研究和临床诊断市场提供各种产品和服务,在Bio-Techne的业务中竞争对手涉及多个领域。
Qiagen NV
QGEN
市值10.16B
Qiagen N.V.为分子诊断、应用测试、学术和制药研究提供样品和测定技术,与Bio-Techne在类似领域竞争。
PERKINELMER INC
PKI
市值16.9B
PerkinElmer, Inc.为诊断、生命科学和应用服务市场提供产品和服务,在多个诊断和研究领域与Bio-Techne竞争。
Bruker
BRKR
市值10.17B
Bruker Corporation 设计和制造科学仪器以及分析和诊断解决方案,与Bio-Techne的分析仪器和试剂竞争。
Repligen
RGEN
市值8.45B
Repligen Corporation提供生物加工技术和解决方案,支持生物药物的开发和生产,在生物技术和制药研究领域与Bio-Techne竞争。

分析师评级

82.8$平均价格目标
最高估值为 $95。
来自过去6个月内的 5 个评级。这不是投资建议。
买入
60%
持有
40%
卖出
0%

关于

Health Technology
Biotechnology
Manufacturing
Biological Product (except Diagnostic) Manufacturing
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Show more...
首席执行官
Charles Kummeth
员工
3100
国家
US
ISIN
US09073M1045

上市公司